Cancer Family
Respiratory System Neoplasm
CI-CAN-00000049Explore in graph →
Non-malignant2,727 active trials51 approved drugs619 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000049Explore in graph →
Clinical trials
11,611 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03568097 | Immunotherapy in Combination With Chemotherapy in Small-cell Lung Cancer(PAVE) | unknown | Phase 2 | 55 | Hellenic Cooperative Oncology GroupOTHER | 1 | Jun 2, 2023 | clinicaltrials |
| NCT05885815 | Application of SERS Technology in Clinical Diagnosis and Prognosis of Lung Cancer Immunotherapy | unknown | — | 500 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 0 | Jun 2, 2023 |
| clinicaltrials |
| NCT05885984 | Acceptance and Commitment Therapy on Fatigue Interference in Patients With Advanced Lung Cancer and Caregiver Burden (ACT) | unknown | N/A | 80 | Chinese University of Hong KongOTHER | 1 | Jun 2, 2023 | clinicaltrials |
| NCT05886075 | A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Relapsed/Refractory Advanced Solid Tumors | unknown | Early Phase 1 | 24 | Shanghai Yunying Medical TechnologyINDUSTRY | 1 | Jun 2, 2023 | clinicaltrials |
| NCT04631731 | Risk Factors of Immune-ChEckpoint Inhibitors MEdiated Liver, Gastrointestinal, Endocrine and Skin Toxicity(ICEMELT) | unknown | Phase 1 / Phase 2 | 200 | Western Sydney Local Health DistrictOTHER | 1 | Jun 1, 2023 | clinicaltrials |
| NCT05498389 | EMB-01 in Combination With Osimertinib in Patients With EGFR Mutant Lung Cancer | unknown | Phase 1 / Phase 2 | 115 | Shanghai EpimAb Biotherapeutics Co., Ltd.INDUSTRY | 2 | Jun 1, 2023 | clinicaltrials |
| NCT03797391 | A Dose Escalation With Expansion Study of EMB-01 in Participants With Advanced/Metastatic Solid Tumors | unknown | Phase 1 / Phase 2 | 186 | Shanghai EpimAb Biotherapeutics Co., Ltd.INDUSTRY | 2 | May 31, 2023 | clinicaltrials |
| NCT04409444 | Manchester Lung Health Study(qUEST) | unknown | — | 9,730 | Manchester University NHS Foundation TrustOTHER_GOV | 1 | May 31, 2023 | clinicaltrials |
| NCT05306652 | Exercise in Extended Oncogene Addicted Lung Cancer in Active Treatment(EXcellenT) | unknown | N/A | 40 | AUSL Romagna RiminiOTHER | 1 | May 31, 2023 | clinicaltrials |
| NCT05882630 | Surufatinib Combined With Serplulimab Plus Chemotherapy in the Treatment of Extensive-stage Small Cell Lung Cancer | unknown | Phase 1 / Phase 2 | 39 | Fujian Cancer HospitalOTHER_GOV | 1 | May 31, 2023 | clinicaltrials |
| NCT04489992 | Experiment on the Use of Innovative Computer Vision Technologies for Analysis of Medical Images in the Moscow Healthcare System | unknown | — | 133,000 | Research and Practical Clinical Center for Diagnostics and Telemedicine Technologies of the Moscow Health Care DepartmentOTHER | 1 | May 26, 2023 | clinicaltrials |
| NCT05873790 | Minimal Residual Disease Dynamic Monitoring in First-Line Serplulimab Plus Chemotherapy in Treatment of Extensive Small Cell Lung Cancer: An Observational Study | unknown | — | 30 | The First Hospital of Jilin UniversityOTHER | 0 | May 24, 2023 | clinicaltrials |
| NCT03094884 | Pulsed Low Dose Rate Radiation With Concurrent Chemotherapy for Non-Small Cell Lung Cancer and Esophageal Cancer | unknown | Phase 1 | 40 | Fox Chase Cancer CenterOTHER | 1 | May 23, 2023 | clinicaltrials |
| NCT04676815 | Narrow Band Imaging (NBI) Under Electronic Bronchoscope in Lung Cancer | unknown | — | 200 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | May 23, 2023 | clinicaltrials |
| NCT04580498 | A Trial of SHR-1701 With or Without Chemotherapy in Patients With Stage III NSCLC | unknown | Phase 2 | 107 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | May 19, 2023 | clinicaltrials |
| NCT05865730 | A Study of Oncobax®-AK in Patients With Advanced Solid Tumors | unknown | Phase 2 | 122 | EverImmuneINDUSTRY | 2 | May 19, 2023 | clinicaltrials |
| NCT05859373 | To Evaluate the Efficacy and Safety of TQB3728 Tablets in Sequential Maintenance of TQB2450 Injection Therapy in Patients After Sequential or Concurrent Chemoradiation for Locally Advanced Non-small Cell Lung Cancer. | unknown | Phase 1 / Phase 2 | 78 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | May 16, 2023 | clinicaltrials |
| NCT05860374 | A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Advanced Solid Tumors | unknown | Early Phase 1 | 20 | Shanghai Yunying Medical TechnologyINDUSTRY | 1 | May 16, 2023 | clinicaltrials |
| NCT04940637 | UNITO-001- Study in HRR/PDL1 Positive MPM/NSCLC(UNITO-001) | unknown | Phase 2 | 70 | University of Turin, ItalyOTHER | 1 | May 12, 2023 | clinicaltrials |
| NCT05854030 | Serum Exosomal miRNA Predicting the Therapeutic Efficiency in Lung Squamous Carcinoma | unknown | — | 60 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | May 11, 2023 | clinicaltrials |
| NCT04202809 | Phase-II Trial of Induction Chemotherapy and Chemoradiotherapy Plus/Minus Durvalumab and Consolidation Immunotherapy in Patients With Resectable Stage III NSCLC.(ESPADURVA) | unknown | Phase 2 | 90 | University Hospital, EssenOTHER | 1 | May 10, 2023 | clinicaltrials |
| NCT05783024 | Advanced Data-Aided Medicine Part Lung Cancer(ADAMpartlung) | unknown | — | 500 | AZ DeltaOTHER | 1 | May 10, 2023 | clinicaltrials |
| NCT05157776 | A Phase III Trial of Neoadjuvant Sintilimab and Chemotherapy for NSCLC Harboring No Driver Mutations | unknown | Phase 3 | 72 | Tongji UniversityOTHER | 1 | May 9, 2023 | clinicaltrials |
| NCT05354882 | Interventional Study on DEterminants and Factors of Physical ACtivity After Treatments in Oncology(DEFACTO2) | unknown | N/A | 150 | Université Sorbonne Paris NordOTHER | 1 | May 9, 2023 | clinicaltrials |
| NCT05850702 | Attenuation of the Hemodynamic Response to Double-lumen Endotracheal Intubation With Nebulized Lidocaine | unknown | Phase 4 | 92 | RenJi HospitalOTHER | 0 | May 9, 2023 | clinicaltrials |
| NCT05847764 | Disitamab Vedotin Combined Therapy for Locally Advanced or Metastatic NSCLC Patients With HER2 Alterations | unknown | Phase 2 | 95 | Sun Yat-sen UniversityOTHER | 1 | May 8, 2023 | clinicaltrials |
| NCT03217669 | Epacadostat (INCB24360) in Combination With Sirolimus in Advanced Malignancy | unknown | Phase 1 | 15 | Chao HuangOTHER | 1 | May 3, 2023 | clinicaltrials |
| NCT04542369 | Pilot Study of PD-1inhibitor (Tislelizumab) Plus Chemotherapy as Neoadjuvant Therapy for Limited-Stage Small-Cell Lung Cancer | unknown | Phase 2 | 15 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | May 3, 2023 | clinicaltrials |
| NCT05099237 | Enhanced Monitoring for Better Recovery and Cancer Experience in Greater Manchester(EMBRaCE-GM) | unknown | N/A | 80 | Manchester University NHS Foundation TrustOTHER_GOV | 1 | May 3, 2023 | clinicaltrials |
| NCT05840094 | Multimodalitic Imaging in the N-stage of Lung Cancer | unknown | N/A | 100 | Peking University First HospitalOTHER | 1 | May 3, 2023 | clinicaltrials |
| NCT05318807 | Personalised Diet, Exercise and Emotional Support for Lung Cancer Patients Having Chemotherapy, Radiotherapy or Immunotherapy Treatment | unknown | N/A | 30 | Imperial College Healthcare NHS TrustOTHER | 1 | May 1, 2023 | clinicaltrials |
| NCT03523468 | Curative Effect and Quality of Life Between Uniportal and Open Sleeve Lobectomy for Central Type Lung Cancer | unknown | Phase 3 | 200 | Lei JiangOTHER | 1 | Apr 25, 2023 | clinicaltrials |
| NCT03827070 | Dry Pleurodesis With Talcum and Afatinib is Used to Treat Patients With Non-Small Cell Lung Carcinoma(DPTA) | unknown | Phase 1 | 12 | Center Trials & Treatment EuropeNETWORK | 1 | Apr 25, 2023 | clinicaltrials |
| NCT05826483 | Almonertinib in the First-line Treatment of Patients of NSCLC With Poor Performance Status | unknown | Phase 1 | 20 | Guangzhou Institute of Respiratory DiseaseOTHER | 1 | Apr 24, 2023 | clinicaltrials |
| NCT03313544 | Evolution of the Heart Function When Monitoring Immunotherapies Anti-cancerous Inhibiting PD-1 | unknown | Phase 4 | 50 | Assistance Publique Hopitaux De MarseilleOTHER | 1 | Apr 21, 2023 | clinicaltrials |
| NCT04922138 | Aumolertinib Adjuvant Therapy of Resectable Stage I EGFRm+ NSCLC With High-grade Patterns(APPOINT) | unknown | Phase 2 | 104 | Baohui HanOTHER | 1 | Apr 21, 2023 | clinicaltrials |
| NCT05819905 | Radiomics for prEdiction of lunG cAncer biologY | unknown | — | 600 | Poitiers University HospitalOTHER | 1 | Apr 19, 2023 | clinicaltrials |
| NCT05258383 | Personalized Estimation of Doses Delivered During Image Guided Radiation Therapy Tests(ELISA) | unknown | — | 320 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Apr 18, 2023 | clinicaltrials |
| NCT05815472 | Advanced Patient Monitoring and A.I. Supported Outcomes Assessment in Lung Cancer Using Internet of Things Technologies (A.I. - APALITT)(APALITT) | unknown | N/A | 50 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Apr 18, 2023 | clinicaltrials |
| NCT05813522 | Furmonertinib in Patients With Leptomeningeal Metastases Associated With EGFR Mutated NSCLC | unknown | Phase 2 | 30 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Apr 14, 2023 | clinicaltrials |
| NCT03908671 | Clinical Study of Personalized mRNA Vaccine Encoding Neoantigen in Patients With Advanced Esophageal Cancer and Non-small Cell Lung Cancer | unknown | N/A | 24 | Stemirna TherapeuticsINDUSTRY | 1 | Apr 13, 2023 | clinicaltrials |
| NCT05778136 | Lung Cancer, Exercise and Force Development | unknown | N/A | 20 | Rigshospitalet, DenmarkOTHER | 1 | Apr 13, 2023 | clinicaltrials |
| NCT05810350 | Aumolertinib Combined Intrathecal Chemotherapy for Leptomeningeal Metastasis From EGFR-Mutated NSCLC and Prognostic Value of Dynamic Changes in cfDNA Profiles | unknown | Phase 2 | 40 | Three Gorges Hospital of Chongqing UniversityOTHER | 1 | Apr 13, 2023 | clinicaltrials |
| NCT05278364 | Phase I/II Study of SY-5007, a RET Inhibitor, in Patients With RET-altered Advanced Solid Tumor | unknown | Phase 1 / Phase 2 | 184 | Shouyao Holdings (Beijing) Co. LTDOTHER | 1 | Apr 12, 2023 | clinicaltrials |
| NCT05641493 | A Phase Ib/II Clinical Trial to Evaluate the Safety and Efficacy of HLX208+HLX10 in NSCLC With BRAF V600E Mutation | unknown | Phase 1 / Phase 2 | 49 | Shanghai Henlius BiotechINDUSTRY | 1 | Apr 10, 2023 | clinicaltrials |
| NCT05805956 | IMM2902 in Patients With Advanced Solid Tumors Expressing HER2 | unknown | Phase 1 / Phase 2 | 105 | ImmuneOnco Biopharmaceuticals (Shanghai) Inc.OTHER | 1 | Apr 10, 2023 | clinicaltrials |
| NCT05807022 | Evaluation of the Safety and Effectiveness of Percutaneous and Transbronchial Argon-helium Cryoablation | unknown | N/A | 60 | China-Japan Friendship HospitalOTHER | 0 | Apr 10, 2023 | clinicaltrials |
| NCT05288569 | irAE Prediction of Anti-PD-1/L1 in Lung Cancer | unknown | — | 120 | Peking Union Medical College HospitalOTHER | 1 | Apr 7, 2023 | clinicaltrials |
| NCT05802771 | Lung Cancer Multi-omics Digital Human Avatars for Integrating Precision Medicine Into Clinical Practice(LANTERN) | unknown | — | 600 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 0 | Apr 7, 2023 | clinicaltrials |
| NCT05803746 | PD-L2 Targeting Nanobody Radiotracer for PET Imaging of Solid Tumor | unknown | N/A | 20 | Peking University Cancer Hospital & InstituteOTHER | 1 | Apr 7, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Jun 2, 2023source: clinicaltrials